Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kapil Bhalla

Showing results (91-100 of 153) with videos related to

Pageof 16
Sort By:
Cancer Research|April 14, 2011
IRF8 regulates acid ceramidase expression to mediate apoptosis and suppresses myelogeneous leukemiaXiaolin Hu, Dafeng Yang, Mary Zimmerman, et al.
Cancer Research|May 20, 2004
Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3Prince George, Purva Bali, Pamela Cohen, et al.
Journal of Medicinal Chemistry|July 17, 2015
Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime β-Catenin Pathway InhibitorsRaffaella Soldi, Stephen K Horrigan, Marek W Cholody, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cellsWarren Fiskus, Michael Pranpat, Maria Balasis, et al.
Leukemia Research|November 7, 2008
Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816VCelalettin Ustun, Christopher L Corless, Natasha Savage, et al.
Blood|March 16, 2006
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cellsWarren Fiskus, Michael Pranpat, Purva Bali, et al.
Cancer|July 1, 2011
High-dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 yearsMartha Arellano, Elliott Winton, Lin Pan, et al.
Blood|September 25, 2004
Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cellsFei Guo, Celia Sigua, Purva Bali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3Purva Bali, Prince George, Pamela Cohen, et al.
American Journal of Hematology|August 11, 2019
Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutationIman Abou Dalle, Hagop Kantarjian, Sarah A Bannon, et al.
Pageof 16

Showing results (91-100 of 153) with videos related to

Sort By:
Pageof 16
Cancer Research|April 14, 2011
IRF8 regulates acid ceramidase expression to mediate apoptosis and suppresses myelogeneous leukemiaXiaolin Hu, Dafeng Yang, Mary Zimmerman, et al.
Cancer Research|May 20, 2004
Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3Prince George, Purva Bali, Pamela Cohen, et al.
Journal of Medicinal Chemistry|July 17, 2015
Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime β-Catenin Pathway InhibitorsRaffaella Soldi, Stephen K Horrigan, Marek W Cholody, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cellsWarren Fiskus, Michael Pranpat, Maria Balasis, et al.
Leukemia Research|November 7, 2008
Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816VCelalettin Ustun, Christopher L Corless, Natasha Savage, et al.
Blood|March 16, 2006
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cellsWarren Fiskus, Michael Pranpat, Purva Bali, et al.
Cancer|July 1, 2011
High-dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 yearsMartha Arellano, Elliott Winton, Lin Pan, et al.
Blood|September 25, 2004
Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cellsFei Guo, Celia Sigua, Purva Bali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3Purva Bali, Prince George, Pamela Cohen, et al.
American Journal of Hematology|August 11, 2019
Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutationIman Abou Dalle, Hagop Kantarjian, Sarah A Bannon, et al.
Pageof 16